M

Mersana Therapeutics

D
MRSN
USD
0.22
(9.4017%)
Market Closed
82,429.00
Volume
-1.82
EPS
-
Div Yield
-3.011765
P/E
314,048,130.56
Market Cap
Today
28.0000%
1 Week
40.659%
1 Month
29.949%
6 Months
-27.479%
12 Months
91.045%
Year To Date
10.108%
All Time
0%

Title:
Mersana Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Do you need help or have a question?